Trial Profile

To determine whether deflazacort is non-inferior to 0.9 mg/kg/d among newly diagnosed patients with Duchenne muscular dystrophy

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 14 Jun 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Deflazacort (Primary)
Indications Duchenne muscular dystrophy
Focus Therapeutic Use
Acronyms DOSE

Most Recent Events

14 Jun 2022 New trial record
01 May 2022 Primary endpoint (change in 6MWD, from baseline to week-24 of intervention) has not been met according to the results published in the European Journal of Paediatric Neurology
01 May 2022 Results published in the European Journal of Paediatric Neurology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com